CRYM

Across TCGA pan-cancer cohorts, CRYM mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CRYM data layer compared with 23 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CRYM mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CRYM expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and PDAC are the cancer types where CRYM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.720	0.173	.002	40	view →
COAD	DFS	Quartile	All	1.000	0.874	.022	24	view →
PDAC	OS	Median	III,IV	0.594	0.249	.007	12	view →
LUAD	OS	Median	II,III,IV	0.759	0.463	.013	10	view →
UCEC	DFS	Median	II,III,IV	0.532	0.869	.035	4	view →
LSCC	DFS	Tertile	III,IV	1.000	0.712	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CRYM–CCRCC (DFS)

Open the CCRCC breakdown →